The preset invention relates to a new method for wound healing, particularly in burns, comprising Epinecidin-1 (Epi-1) or Pardaxin (GE33), optionally in the incorporation into collagen.

This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry, said slurry comprising a plurality of natural or synthetic polymer fibers and at least one suspension fluid, wherein the polymer fibers are substantially evenly dispersed and randomly oriented throughout the volume of the suspension fluid; applying a force, e.g., centrifugal, to said vessel containing said slurry, whereupon said force serves to cause said polymer fibers to migrate through the suspension fluid and amass at a furthest extent of the vessel, forming a polymer material, with said polymer material comprising polymer fibers of sufficient length and sufficiently viscous, interlaced, or interlocked to retard dissociation of said polymer fibers.

The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.

Methods and systems for stiffening of tissue are presented to allow improved processing. Solutions comprising an acid or a base can be contacted with tissue to stiffen one or more components of the tissue. The resulting stiffened tissue can be used in the creation of wound treatment devices.

The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.

The present invention provides a method of producing a modified collagen, including the steps of: providing a collagen comprising a SS bond; introducing a SH group in said collagen comprising a SS bond by reduction of the SS bond to provide a collagen thiol comprising a SH group; and nitrosating the SH group of the collagen thiol to provide a modified collagen, said modified collagen comprising S-nitroso groups.

Medical dressings include a non-woven polymeric nanofiber mat embedded within a chitosan hydrogel matrix. The dressings may be obtained by electro spinning of polymeric nanofibers and thereafter incorporating a chitosan hydrogel into interstices of the mat by vacuum or positive pressure assistance. The resulting medical dressings may be optically transparent (e.g., at least about 50% up to about 95% light transmittance), flexible, and mechanically robust. The dressings may also incorporate self-adhesion promoters to allow self-adhesion to biological tissue, e.g., ocular surfaces, and/or therapeutic agents which are capable of delivering therapeutics (e.g. stem cells, drugs and the like) to the tissue surface. The dressings are especially useful as ocular bandages for the treatment and repair of ocular wounds.

Medical dressings include a non-woven polymeric nanofiber mat embedded within a chitosan hydrogel matrix. The dressings may be obtained by electro spinning of polymeric nanofibers and thereafter incorporating a chitosan hydrogel into interstices of the mat by vacuum or positive pressure assistance. The resulting medical dressings may be optically transparent (e.g., at least about 50% up to about 95% light transmittance), flexible, and mechanically robust. The dressings may also incorporate self-adhesion promoters to allow self-adhesion to biological tissue, e.g., ocular surfaces, and/or therapeutic agents which are capable of delivering therapeutics (e.g. stem cells, drugs and the like) to the tissue surface. The dressings are especially useful as ocular bandages for the treatment and repair of ocular wounds.

Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived growth factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using doing procedures leading to effective results with a minimal number of treatment applications are also described.

The present invention refers to a process to obtain a three-dimensional (3D) biodressing comprising the steps of (a) isolating and culturing mesenchymal cells with human AB serum; (B) performing three-dimensional (3D) bioprinting using a biomaterial such as sodium alginate and cells obtained in step a; (c) putting at rest the 3D biodressing obtained after bioprinting; (d) covering the 3D biodressing with a 100 mM calcium chloride solution; (e) washing the 3D biodressing; (f) adding Dulbecco's Modified Eagle Medium (DMEM); and (g) keeping the biodressing in an incubator for up to 15 days. Additionally, the present invention refers to the 3D biodressing obtained comprising, preferably 4% sodium alginate and mesenchymal cells from the umbilical cord (MCUs), which has healing, anti-inflammatory, and analgesic properties. Furthermore, the present invention relates the 3D biodressing to treat patients with chronic wounds and severe burns.